Ivacaftor deuterated - Vertex Pharmaceuticals

Drug Profile

Ivacaftor deuterated - Vertex Pharmaceuticals

Alternative Names: C-10355; C-10358; CTP-656; D-ivacaftor; Deuterated ivacaftor; VX 561

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Amides; Aminophenols; Organic deuterium compounds; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 03 May 2018 Phase-I development in Cystic-fibrosis (In volunteers) ongoing in Australia (PO)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in Australia (PO)
  • 31 Jan 2018 Vertex plans a phase III programme of VX 445 in triple combination with tezacaftor and VX 561 for Cystic fibrosis (Combination therapy) in June 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top